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ABSTRACT

EXTRACELLULAR MATRIX NANOPARTICLES EFFECTS ON THE LUNG IN VIVO
By Brittaney Ritchie
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Biomedical Engineering at Virginia Commonwealth University.
Virginia Commonwealth University, 2020

Director: Rebecca L. Heise, Ph.D.,
Associate Professor, Department of Biomedical Engineering

Acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes
diffuse alveolar damage and a loss of the extracellular matrix (ECM). This leads to pulmonary
edema and lung function deterioration. Our lab has created decellularized porcine lung,
electrosprayed ECM nanoparticles that have been previously shown to have pro-regenerative
capabilities in vitro.
In this study, the ECM nanoparticle effects on young murine lungs were tested in vivo. An
ECM nanoparticle suspension, previously used for the in vitro studies, was aerosolized
intratracheally into the lungs using a microsprayer. 24 hours later, the lung mechanics,
bronchoalveolar lavage fluid, and histology were evaluated.
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The ECM nanoparticles had no significant damaging effects to the lungs and were
comparable to the control groups. Further studies are being done to establish an ARDS model
using the ECM nanoparticle treatment.
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CHAPTER 1
INTRODUCTION

1.1 Lung Anatomy and Physiology
The respiratory system is responsible for the gas exchange of oxygen and carbon dioxide. The
inspired air from the environment brings in oxygen that can be passed into the bloodstream,
where it can circulate to the cells in the rest of the body. When breathing takes place, air passes
through the respiratory tract, which divides distally into two specific zones: the conducting zone
and the respiratory zone (Figure 1).1

Figure 1. Diagram of the conducting and respiratory airways. 2
12

1.2 Conducting and Respiratory Zones
The conducting zone provides a continuous passageway for air to move into and out of the
respiratory airways. The main function of the conducting zone is not only to provide pulmonary
ventilation, but also to warm, moisten, and filter the air prior to reaching the gas exchange region.
Filtration of small inhaled particles occurs by the mucus-secreting and ciliated cells that line the
conducting zone. This zone is comprised of the nose, nasopharynx, larynx, trachea, bronchi,
bronchioles, and terminal bronchioles. The structure of the lungs involves twenty-three divisions
into increasingly smaller airways from the trachea to the alveoli in the respiratory zone. 1,2,3
The respiratory zone is comprised of the respiratory bronchioles, alveolar ducts, and
alveolar sacs. Each of these structures participates in gas exchange and are lined with alveoli at
varying amounts. Alveoli are sparsely located along the walls of the respiratory bronchioles, and
the alveoli lining the alveolar ducts are sacs are more numerous in comparison.1

1.3 Alveolar Structure and Function
A large portion of the lung, approximately 90% of its total volume, is comprised of the alveolar
region where the alveoli reside and where gas exchange occurs (Figure 2).4 Separating each
adjacent alveoli is the alveolar wall or interalveolar septum. The interalveolar septum not only
separates adjacent alveoli, but also separates the alveolar air space from the blood-filled
capillaries.1,4,5
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Figure 2. Diagram of lung alveolar structure.5

The interalveolar septum is comprised of two types of alveolar epithelial cells: type I (ATI)
and type II alveolar epithelial cells (ATII). ATIs are thin, squamous cells that line the alveolar
septum and are known to maintain the homeostasis of the alveoli.4,6,7,8 ATIIs are cuboidal cells
that function in renewal and repair. ATIIs synthesize and secrete surfactants, which reduce the
surface tension of at the air-liquid interface; and serve as the alveolar progenitor cells. 4,7,8,9 ATIIs
differentiate into ATI cells when damage to ATIs occur. 4,7,8 Together, these two cell types form
the epithelial barrier and prevent fluids from entering the alveoli.
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1.4 Lung Extracellular Matrix
The extracellular matrix (ECM) is necessary for normal functionality, physical support, and
delivers cues that drive cellular differentiation.10 In the lung, the ECM determines airway
structure and is organized into the basement membrane and interstitial spaces.10-12 The
basement membranes are thin sheets of glycoproteins found under the epithelial and endothelial
cell layers that surround muscle, fat, and peripheral nerve cells. 10,12 The interstitial spaces form
the parenchyma of the lung which maintains the cohesiveness and biomechanical characteristics
of the lung (Figure 3).10,12
A major portion of the lung’s ECM protein content is made up of collagen; types I, II, III,
V, and XI.12, 13 Type I collagen is within the alveolar wall, type III is within the alveolar septa and
interstitium of the alveoli, and type IV is within the epithelial and endothelial basement
membranes.13 The ECM is also made up of a fibrous proteins, glycoproteins, and proteoglycans. 10,
12, 14

It is important to maintain the integrity of the lung in order to maintain proper lung
function. Thus, it is important to maintain normal lung ECM and treat any lung ECM damage that
can often be a result of pulmonary diseases.

15

Figure 3. Diagram of the healthy lung ECM. a. The healthy lung ECM contains fibroblasts,
collagens, elastin, and fibronectin. b. Legend of molecules and cell types. 12
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CHAPTER 2
ACUTE RESPIRATORY DISTRESS SYNDROME

2.1 Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) is a life-threatening condition with a high mortality
rate that is usually caused by pneumonia, severe sepsis, aspiration of gastric contents, or major
trauma.15,16 This syndrome is characterized by the filling of the alveoli with protein-rich
pulmonary edema, which leads to hypoxemia and reduced lung compliance.16, 17 Diffuse alveolar
damage occurs, and the injury to the alveolar capillaries disrupts the endothelial barrier and
causes damage to the ECM.18 This alveolar-capillary barrier damage and increased vascular
permeability allow for fluid to fill the alveoli. As the air space fills with fluid, lung function
deteriorates, and gas exchange is impaired.16, 17, 18

2.2 Macrophage Phenotypes
The first responders of the immune response are the macrophages. Macrophages can either
phagocytose foreign objects or initialize an immune cascade by releasing cytokines that can
recruit other immune cells to the injury site. 28 Macrophages have two polarization states: the
classically activated, pro-inflammatory M1 state and the alternatively activated, antiinflammatory M2 state.19 M1 macrophages are responsible for inflammatory signaling, and M2
macrophages contribute to tissue healing process.20 Previous studies have observed that the M1
macrphages kill infectious organisms and virus-infected cells; however, this can come at the price
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of resulting collateral tissue damage. In healty issue, macrophages tend to polarize to the M2
phenotype, which has been shown to provide growth factors and heal damaged tissues. 21
In ARDS, when alveolar macrophages are activated, inflammatory cytokines, such as IL1β, TNF-α, IL-6, and IL-8, are secreted. These cytokines stimulate chemotaxis and activate
neutrophils.16

2.3 Neutrophil-Dependent Injury
Neutrophils are part of the immune system and are types of white blood cells that play a vital
role in the defense against infection. 22 Neutrophils become activated and are recruited to the
injury site where the infection or trauma to the body has occurred. However, the immune system
can become hyperactivated as a response to infection or trauma, and activated neutrophils have
the potential to cause cell-mediated damage at remote organs.23
In the case of ARDS, significant amounts of neutrophils accumulate in the lung
microvasculature and release several toxic mediators, such as proteases and pro-inflammatory
cytokines, that damage the lung endothelial and alveolar epithelial regions (Figure 4). Both lung
endothelial and alveolar epithelial damage must occur for the injury to be diagnosed as ARDS.
Lung endothelial damage is the first to occur and endothelial and epithelial damage is often
caused by the influx of neutrophils. 16, 18, 23
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Figure 4. Overview of the pathogenesis of ARDS. Left hand side: The normal alveolus. Right hand
side: The injured alveolus during the acute phase of ARDS. When alveolar macrophages are
activated, inflammatory cytokines, such as IL-1β, TNF-α, IL-6, and IL-8, are secreted. These
cytokines stimulate chemotaxis and activate neutrophils. Neutrophils adhere to the injured
capillary endothelium and enter into the pulmonary edema filled interstitium; which then release
several toxic mediators, such as proteases and other proinflammatory cytokines. This results in
increased vascular permeability. 16
19

2.4 ARDS ECM Damage
In order for the lung to function properly, the ECM integrity must be maintained. ARDS leads to
damages and changes to the ECM which include: altered alveolar septa with lung fibrosis;
increased amounts of collagen, elastic fibers, and fibronectin; and increased levels of matrix
metalloproteinases (MMP).18,24 MMPs can degrade all known components of the ECM which
effects the regulation of cell growth, cell proliferation, cell survival, and cell migration. 18 Higher
expressions of MMP-9, and in some cases MMP-2, are often seen in human patients and in
animal models with ARDS and appears to be a central component of lung injury.18,24 The
underlying mechanism is not well understood; however, targeting the ECM, and thus the MMPs,
may be critical for the development of potential therapies for ARDS.18

2.5 Treatment
Currently, there is no cure or effective therapeutic for ARDS. Treatments focus on supportive
patient care and include providing respiratory support through mechanical ventilation and fluid
management. The treatments tend to focus on the symptoms rather than the syndrome and are
designed to: increase oxygen delivery, decrease oxygen consumption, and avoid further injury.
16, 25, 26

In addition to the high mortality rate associated with ARDS, patients who manage to

survive have lasting health complications; thus, there is a need for further treatment options.

20

CHAPTER 3
EXTRACELLULAR MATRIX NANOPARTICLES

3.1 Extracellular Matrix Nanoparticles
Decellularized ECM is usually composed of proteoglycans, growth factors, and fibrous proteins,
such as collagens, elastins, fibronectins, and laminins.27,28 ECM is known to promote normal
tissue repair due to their degradation products. The degradation products are known to have
chemoattractant

29, 30, 31

and antimicrobial

31, 32, 33

properties, and these properties have been

utilized in recent lung injury studies. Porcine urinary bladder ECM has been shown to promote
epithelial wound repair and protect against pulmonary fibrosis.34 In another study, inhaled
porcine lung ECM microparticle (< 3 μm) solutions were shown to reduce oxidative damage in an
acute lung injury model.35 Previous studies in our lab have improved upon these recent studies
by creating porcine lung ECM nanoparticles that maintain their pro-regenerative benefits and
may improve lung deposition to the distal regions of the lung that are most affected by ARDS. 33

3.2 ECM Nanoparticle Characteristics: Size
Current devices for aerosolized therapeutics have yet to be able to deposit necessary drugs
throughout the total lung. For instance, devices such as the metered-dose inhalers and the dry
powder inhalers are only able to deposit about 10-20% and 12-40% of the emitted drug dose to
the lungs, respectively. 24, 36, 37 This may be partially due to the microparticle sized drugs that are
often used in these inhalers. 38, 39 Particles delivered to the lung must have a diameter size range
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of 260-500 nm in order to reach the alveoli. 40-42 The size of our ECM nanoparticles is 225 (± 67)
nm, which is an optimal diameter size needed to reach the distal region of the lungs (Figure 5). 33

Figure 5. ECM nanoparticles. A scanning electron micrograph of the particles deposited on
aluminum foil. Scale bar is 1 μm. This image was reproduced with permission from the Wiley
Online Library. 33

3.3 ECM Nanoparticle Characteristics: Surface Charge, Cytotoxicity & Pro-regenerative Effects
An indicator of improved biocompatibility and low cytotoxic effects is a negative surface charge,
or ζ-potential, and studies in our lab have proven that the nanoparticles have a slightly negative
charge and are not toxic in vitro. The nanoparticles increased the proliferation of lung epithelial
cells, specifically A549 cells at 24 and 48 hours. The nanoparticles also increased the M2-type
macrophage surface marker CD206 and decreased the M1-type macrophage surface marker
CD11c; inducing a pro-regenerative macrophage phenotype when added to bone-marrow
derived macrophages 33.
22

CHAPTER 4
RESEARCH DESIGN

4.1 Overview
The particle size, ζ-potential, and passive degradation of our ECM nanoparticles have previously
been characterized.33 In addition, the cytotoxicity and the ability to shift macrophages to a proregenerative phenotype have also been characterized in vitro.33 However, our ECM nanoparticles
have yet to be tested in vivo. We hypothesized that the nanoparticles would not negatively
impact the lung mechanics or cause inflammation. To test this hypothesis, the nanoparticles were
aerosolized into young murine lungs using a microsprayer at similar concentrations previously
used in vitro.33 24 hours after ECM nanoparticle aerosolization into the lungs, the lung mechanics,
bronchoalveolar lavage fluid (BALF) cell counts, and histology were evaluated.

4.2 Specific Aim
Specific Aim: Evaluate the lung mechanics, BALF cell counts, and histology after nanoparticle
aerosolization into an in vivo murine model.
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CHAPTER 5
IN VIVO STUDY

5.1 Rationale
In vivo testing was performed to ensure that the lungs remained unharmed when the
nanoparticles were aerosolized within them. To ensure that the nanoparticles were safe to be
used in vivo, the lung mechanics, cytological analysis, and histology were compared among a
control group and 0.125 mg/mL ECM nanoparticle solution concentration that has been
previously used in vitro.

5.2 Methods
* Adapted from [33], [43], and [47]

5.2.1 Decellularizing Porcine Lung Tissue
Porcine lungs were obtained from Smithfield-Farmland slaughterhouse to produce decellularized
ECM powder. Decellularization was achieved with tracheal and vascular detergent perfusion of
sterile 1x phosphate-buffered saline (PBS), 0.1% triton X-100, 2% sodium deoxycholate, 1M
sodium chloride, and DNAse over 3 days in 4oC. After decellularization, the lung should be clear
and white. Large cartilaginous airways were removed, and the remaining alveolar and small
airway structures were lyophilized for 48 hours before freeze-milling into a fine powder. The fine
powder was stored at -20oC until needed.
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5.2.2 Nanoparticle Formation through Electrospray Deposition
PLECM powder was digested for 48 hours at room temperature in 80% v/v glacial acetic acid in
ultrapure H20. After 48 hours, the solution was drawn up in a 10 mL syringe fitted with a 26-gauge
blunt needle (IntelliSpense) and attached to a syringe pump (Kent Scientific, GenieTouch™) set
to 10 mL/hour. The syringe pump was placed on the top of a 1/2” Delrin® (polyoxymethylene)
box with a hole drilled into it for the syringe to pass through. Inside the box, the blunt needle tip
was connected to the voltage generator (Spellman CZE1000R) and grounded to aluminum foil
located approximately 10 cm away from the blunt needle tip. The voltage difference, at 25 kV,
between the blunt needle tip and aluminum foil caused nanoparticle formation through rapid
liquid evaporation (Figure 6).
The nanoparticles were removed from the foil using sterile 1x PBS and lyophilized for 48
hours to form a powder. The nanoparticle powder was diluted using sterile 0.9% saline to 0.125
mg/mL protein concentration. Since the ECM nanoparticle solution begins to degrade after a
month, fresh ECM nanoparticles for new solutions were made prior to each in vivo experiment.

Figure 6. Overview of the process to produce ECM nanoparticles. Decellularized PLECM is acid
digested and electroprayed into nanoparticles.
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5.2.3 Animals
This study was approved by the VCU Institutional Animal Care and Use Committee (protocol
number AD10000465). Wild type, young adult male and female C57BL/6 mice (age, 8-10 weeks;
weight, 22-25 g; Charles River Laboratories) were used in these experiments. The mice were
maintained at a constant temperature (23oC) with free access to food and water under a 12‑h
light/dark cycle condition. All animal experiments were conducted in accordance with the IACUC
University guidelines.

5.2.4 Treatment Groups
Each subject was randomized into the following treatment groups: saline/saline (S/S) or
saline/ECM (S/ECM). An hour before treatment, 50 μL of 0.9% sterile saline was aerosolized
intratracheally (IT) using a Penn-Century MicroSprayer® aerosolizer (Philadelphia, PA) (Figure 6).
Treatment, either 50 μL of 0.9% sterile saline (control) or 50 μL of 0.125 mg/mL sterile ECM
nanoparticle solution, was aerosolized IT using the MicroSprayer® aerosolizer. Each subject’s
recovery was monitored, and once responsive, the subjects were moved to the vivarium for 24
hours prior to mechanical ventilation (Figure 7).

5.2.5 Intratracheal Aerosolization
Prior to IT instillation, subjects were anesthetized with an intraperitoneal (IP) injection of 80
mg/kg sodium pentobarbital. Each anesthetized subject was placed on a slanted board (45° from
vertical) in the supine position and was supported by suture under the upper incisors. 44 The
trachea was illuminated with a microscope lamp. Blunted forceps were used to help displace the
26

tongue for complete trachea exposure.45 After a clear view of the trachea, the MicroSprayer®
aerosolizer was used to aerosolize 50 μL of the 0.125 mg/mL ECM nanoparticle solution IT (Figure
6). Approximately 70 μL of solution was lost in the MicroSprayer® aerosolizer; thus, 70 μL of air
was pushed behind the 50 μL of solution to ensure complete delivery into the lungs. Once the
solution was sprayed, the subject was immediately taken off the support.

Figure 7. Solution aerosolization route using the Penn-Century MicroSprayer®
aerosolizer. 46
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5.2.6 Mechanical Ventilation
24 hours after IT treatment, subjects were anesthetized with an IP injection of 80 mg/kg sodium
pentobarbital prior to experimentation. The depth of subject anesthesia was monitored
continuously using an electrocardiogram transducer monitor included in the FlexiVent small
animal ventilation hardware (SCIREQ Scientific Respiratory Equipment Inc). To maintain an
appropriate level of anesthesia over the course of intubations, sodium pentobarbital redoses of
40 mg/kg were administered as needed when a subject’s heart rate increased by 10% compared
to the baseline heart rate.
In addition to the anesthesia, the mechanical ventilation protocol required an IP
administration of 0.8 mg/kg pancuronium bromide to prevent spontaneous breathing that could
skew mechanical data.
In order to collect lung mechanic data, subjects were mechanically ventilated for 10
minutes on non-injurious settings with 30 cmH20 peak inspiratory pressure (PIP), 150 breaths per
minute, 3 cmH20 positive end expiratory pressure (PEEP) using a FlexiVent small animal ventilator
(SCIREQ) (Figure 8).
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Figure 8. Overview of the in vivo studies testing the effects of the ECM nanoparticle solution at
0.125 mg/mL.

5.2.7 Lung Mechanics
Snapshot-150 v7.5 and Deep Inflation v7.5 were performed using the included FlexiWare
software package (SCIREQ). Snapshot measures lung tissue compliance: resistance, compliance,
and elastance. Deep inflation measures the inspiratory capacity or total lung capacity.

5.2.8 Bronchoalveolar Lavage
A bronchoalveolar lavage was performed three times using 500 μL of cold, sterile 1x PBS each
time. The PBS was instilled into the lungs using a tracheal cannula. Lungs were slowly inflated
and deflated to ensure no airway rupturing. 1.5 mL of total bronchoalveolar lavage fluid (BALF)
per subject was obtained using this technique.
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5.2.9 BALF Cytology
BALF was centrifuged at 400 × g, 4 °C for 10 minutes. The supernatant was removed, and the cell
pellet was re-suspended in 3 mL of ammonium-chloride-potassium lysing buffer to lyse and
remove the red blood cells. The solution was centrifuged at 400 × g, 4 °C for 10 minutes and the
supernatant was removed. The cell pellet was re-suspended in 1.5 mL of sterile 1x PBS and 90 μL
was removed for total cell counts. The solution was centrifuged a final time at 400 × g, 4 °C for
10 minutes and the supernatant was removed. The cell pellet was re-suspended in 300 μL of
sterile 1x PBS.
Using a cytospin device (Shandon), cells were then mounted onto glass slides. Cells were
stained using a 3 Diff-Quik solutions staining kit and cover-slipped. Cell populations were then
analyzed using microscopy (Olympus), and the ratios of lymphocytes, monocytes, and
neutrophils were determined.

5.2.10 Lung Histology
Left lungs fixed with 4% paraformaldehyde, sectioned, and H&E stained. Stained slides were
imaged using an Olympus IX71 Microscope (Olympus).

5.2.11 Statistical Analysis
GraphPad Prism 6 statistical analysis software were used for all quantitative experimental
studies. All quantitative experimental studies were performed with a minimum of n = 2. Lung
mechanic statistics were performed using an unpaired t-test with Welch’s correction. BALF
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cellularity percentage statistics were performed using a two-way ANOVA test. P values of < 0.05
were considered significant.

5.3 Results
5.3.1 Lung Mechanics
Lung mechanics of both the S/S group (control) and the S/ECM group were measured 24 hours
after IT aerosolization using the SCIREQ FlexiVent software. The lung resistance of the S/ECM
group was slightly more resistance than the S/S group. The inspiratory capacity of the S/ECM
group lungs was slightly lower than the S/S group. However, the lung resistance, compliance,
elastance, and inspiratory capacity showed no significant difference between the two groups
(Figure 9).
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Figure 9. Lung mechanics. There is no significant difference in lung resistance, compliance,
elastance, or inspiratory capacity between the control group and S/ECM group. A. Lung
resistance. Although the lungs of the S/ECM group were slightly more resistant compared to the
control, S/S, group, there was no significant difference in lung resistance between the two. B.
Lung compliance. There was no significant difference in lung compliance between the two. C.
Lung elastance. There was no significant difference in lung elastance between the two. D.
Inspiratory capacity. There was no significant difference in the lung inspiratory capacity. Data are
presented as mean ± standard deviation; N = 2 for S/S and 3 for S/ECM.
32

5.3.2 Cytology
Cytological differences were measured in the BALF of the S/S and S/ECM groups following lung
mechanic measurements. Amongst the percentages of lymphocytes, monocytes, and
neutrophils, no statistically significant differences were observed between the S/S and S/ECM
groups (Table 1).

Table 1. BALF cellularity. Data presented as the percentage of counted cells. There is no
significant difference in the BALF cellularity between the S/S and S/ECM groups. Data are
presented as mean ± standard deviation; N = 2 for S/S and 2 for S/ECM.
S/S

S/ECM

Lymphocytes (%)

1.79 ± 0.19

2.83 ± 1.18

Monocytes (%)

97.05 ± 1.45

96.50 ± 1.65

Neutrophils (%)

0.17 ± 0.23

0.33 ± 0.00
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5.3.3 Histology
Histology of the S/S and S/ECM lung sections were similar regarding thin alveolar septa and
minimal presence of inflammatory cells in the alveolar septa and alveoli (Figure 10).

Figure 10. Histological H&E images of A. S/S and B. S/ECM lung sections, respectively. Scale bar
is 100 μm.

5.4 Discussion
The results from the in vivo study have proven that the ECM nanoparticles do not induce an
inflammatory response or unnecessary harm to the lungs when aerosolized IT. There was no
statistically significant difference in the lung mechanics or neutrophil cell count between the S/S
and S/ECM group. However, it is important to note that this study was preliminary and the nvalues of each experiment were low. The n-values of the lung mechanics for S/S was 2 and for
S/ECM was 3. The n-values of the BALF cellularity for S/S and S/ECM was 2. Furthermore, the
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histological lung sections of both groups showed thin alveolar septa and minimal inflammatory
cells in the alveoli.
Lung mechanics indicate the functionality of the lung. In this study, resistance,
compliance, elastance, and inspiratory capacity were quantified. Resistance is an indicator for
the level of constriction in the lungs; the ease at which air moves through the lungs. Compliance
describes the ease at which the lungs expand. Elastance is the opposite of compliance and
measures lung stiffness; or resistance to stretch. Inspiratory capacity or total lung capacity is a
measure of the amount of air that can be inhaled at the end of expiration. 48, 49 Since the lung
mechanics of the S/ECM group were not statistically significant and comparable to the control
group, this indicates that the lungs of the S/ECM functioned similarly to normal lungs and that
the ECM did not disrupt normal lung function. This is the first known study on lung mechanics
using inhaled, decellularized, ECM nanoparticle treatments; however, these lung mechanic
results were comparable to C57BL/6 mice that acted as control groups in ventilator induced lung
injury models.
A previous study investigating simvastatin as an injurious mechanical ventilation
protection for mice showed control group lung resistance, compliance, and elastance data.50 The
lung resistance and elastance of our mice showed slightly lower results compared to this study,
which could be due to the IT treatment injections that were used in our study compared to the
IP treatment injections of Manitsopoulos et. al. The IT injections of saline could cause insignificant
inflammation that could skew the lung mechanic results. The lung compliance, however, was
almost identical to the zero timepoint in Manisopoulos et. al..50 The lung inspiratory capacity of
our study is also comparable to a previous study that used a Tpl2 inhibitor as a possible way to
35

protect against mechanical ventilation-induced lung injury.51 Similar to the lung resistance and
elastance previously discussed, the inspiratory capacity results of our study were slightly lower
compared to Kaniaris et. al. This could also possibly be due to the use of IP treatment injections
compared to our IT treatment injections, which may cause insignificant lung inflammation.51
The recruitment of lymphocytes and neutrophils to the site of injury is part of the normal
wound healing process.47 In ARDS, mentioned in chapter 2, epithelial and endothelial lung injury
occurs as a consequence of neutrophil influx.52 The experimental data from this study revealed
that there was no significant difference in the cell counts, as expected based on the lung
mechanics. The neutrophil and lymphocyte counts were low in both the control and S/ECM
group, indicating no inflammatory response or lung injury caused by the nanoparticles.
The lack of inflammatory cells was also evident in the control and S/ECM histological lung
sections and septal thickening, another sign of injury, was not apparent in the S/ECM lung
sections, as to be expected. 52 A previous study explored the therapeutic potential of inhaled
ECM given intratracheally in an acute lung injury rat model.35 The hyperoxic rats treated with
inhaled ECM showed significantly reduced alveolar septal thickening, tissue edema and cell/fluid
exudation, which was evident in their histological lung sections.35 Although, the study did not
have a similar S/ECM group, the inhaled ECM did not cause any harm, which is similar to the
results from our study.
Based on the results of this study, aerosolized ECM nanoparticles are not harmful to the
lungs in vivo.
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CHAPTER 6
CONCLUSION & FURTHER DIRECTIONS

We have shown that our ECM nanoparticles do not cause any unwanted harm in vivo. The ECM
contains tissue-specific components that promote tissue repair and, more specifically, promote
epithelial wound repair.35 ECM may be a potential therapeutic for ARDS because of the ECM’s
ability to promote tissue repair, which is an advantage to repairing the barrier loss caused by
ARDS. However, further studies are needed to show the ECM nanoparticles’ therapeutic potential
in vivo.
Currently, studies are being conducted to determine the distribution of the nanoparticle
solution within murine lungs by fluorescently labeling the nanoparticles with Texas Red™ 1,2Dihexadecanoyl-sn-Glycero-3-Phosphoethanolamine, Triethylammonium Salt (Figure 11).

Figure 11. Overview of the process to produce fluorescently labelled ECM nanoparticles.

Further studies are also being done to fully establish an ARDS in vivo model to test the
effectiveness of the ECM nanoparticles on lung injury. Several studies have been done to
establish the timepoints and dosing concentrations for the future ARDS model; however, we are
still working on the best ARDS model for this potential treatment.
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The in vivo study, described in chapter 7, was designed to be used in association with the
injurious model using lipopolysaccharide (LPS), which is the reason for the hour timepoint prior
to the nanoparticle treatment, but the model has changed drastically since those initial studies.
Establishing the model began by IP injecting 10 mg/kg of LPS into C57BL/6 mice an hour
prior to the ECM nanoparticle treatment, at the same 0.125 mg/mL concentration and collecting
lung mechanics and BALF at 6, 12, and 24 hours.53-57 However, we concluded that the IP injections
of LPS did not cause enough significant lung injury to lead to an effective ARDS model. It was also
concluded that the 12-hour timepoint was the most effective due to the low mice survival rate
at the 24-hour timepoint.
Due to the ineffectiveness of the IP injections, we instead used an IT injection at a 2 mg/kg
LPS concentration an hour prior to treatment and collected lung mechanics and BALF at 12
hours.58, 59 We concluded that the IT injections at a 2 mg/kg LPS concentration was effective, but
the use of the microsprayer for both IT injections was causing additional, unwanted inflammation
in the lungs (Figure 12). Future studies will involve determining if aspirating will be a more
effective aerosolization technique that will not cause unwanted inflammation in the lungs.
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Figure 12. Overview of the injurious model in vivo studies testing the effects of the ECM
nanoparticle solution at 0.125 mg/mL.

This investigation, nonetheless, demonstrates the potential for the ECM nanoparticles to
be used as a therapeutic to treat ARDS, but a large amount of work still needs to be done to fully
establish a working ARDS in vivo model.
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